KR20230113742A - 난소암의 검출 및 치료를 위한 방법 - Google Patents

난소암의 검출 및 치료를 위한 방법 Download PDF

Info

Publication number
KR20230113742A
KR20230113742A KR1020237017397A KR20237017397A KR20230113742A KR 20230113742 A KR20230113742 A KR 20230113742A KR 1020237017397 A KR1020237017397 A KR 1020237017397A KR 20237017397 A KR20237017397 A KR 20237017397A KR 20230113742 A KR20230113742 A KR 20230113742A
Authority
KR
South Korea
Prior art keywords
ovarian cancer
subject
das
n3ap
diacspmd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017397A
Other languages
English (en)
Korean (ko)
Inventor
조핸스 페르만
사미르 한나쉬
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20230113742A publication Critical patent/KR20230113742A/ko
Pending legal-status Critical Current

Links

Classifications

    • G01N33/57449—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
KR1020237017397A 2020-10-29 2021-10-27 난소암의 검출 및 치료를 위한 방법 Pending KR20230113742A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107160P 2020-10-29 2020-10-29
US63/107,160 2020-10-29
PCT/US2021/056852 WO2022093960A1 (en) 2020-10-29 2021-10-27 Methods for the detection and treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
KR20230113742A true KR20230113742A (ko) 2023-08-01

Family

ID=81383153

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017397A Pending KR20230113742A (ko) 2020-10-29 2021-10-27 난소암의 검출 및 치료를 위한 방법

Country Status (7)

Country Link
US (1) US20240044902A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237090B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548110A (cg-RX-API-DMAC7.html)
KR (1) KR20230113742A (cg-RX-API-DMAC7.html)
CN (1) CN116490776A (cg-RX-API-DMAC7.html)
CA (1) CA3196725A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022093960A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4558824A4 (en) * 2022-07-21 2026-07-08 Univ Texas METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER
KR20250017689A (ko) 2023-07-27 2025-02-04 가톨릭대학교 산학협력단 난소암 발병 위험률 예측 방법 및 분석장치

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081569A1 (ja) * 2003-03-11 2004-09-23 Trans Genic Inc. 腫瘍マーカーとしてのn1,n12-ジアセチルスペルミン
JP2007502983A (ja) * 2003-08-15 2007-02-15 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション がん検出のための多因子アッセイ
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2009006439A1 (en) * 2007-06-29 2009-01-08 Correlogic Systems, Inc. Predictive markers for ovarian cancer
CN108508168B (zh) * 2012-02-23 2021-08-17 学校法人庆应义塾 并用抗癌剂的感受性判定标记
WO2013188391A2 (en) * 2012-06-11 2013-12-19 Georgia Regents University Biomarkers for ovarian cancer
GB201316347D0 (en) * 2013-09-13 2013-10-30 Cancer Rec Tech Ltd Biological fluid filtration assembly
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers
CA2933005C (en) * 2015-06-12 2024-01-23 Brock University Methods and compounds for enhancing contrast in magnetic resonance imaging (mri)
TW201800408A (zh) * 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
HRP20240136T1 (hr) * 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
ES2995959T3 (en) * 2017-02-09 2025-02-11 Univ Texas Methods for the detection and treatment of lung cancer
WO2019178216A1 (en) * 2018-03-13 2019-09-19 Baylor Research Institute Methods and compositions for treating, diagnosing, and prognosing ovarian cancer
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー
CN109870579B (zh) * 2019-02-03 2022-02-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒

Also Published As

Publication number Publication date
US20240044902A1 (en) 2024-02-08
EP4237090A4 (en) 2024-09-25
CA3196725A1 (en) 2022-05-05
CN116490776A (zh) 2023-07-25
EP4237090A1 (en) 2023-09-06
WO2022093960A1 (en) 2022-05-05
EP4237090B1 (en) 2026-02-18
JP2023548110A (ja) 2023-11-15

Similar Documents

Publication Publication Date Title
CN108957006B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
US20220042998A1 (en) Biomarkers for pancreatic cancer
CN108603887B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
US20160188835A1 (en) Biomarkers
CN104204798A (zh) 膀胱癌的生物标志物和使用所述生物标志物的方法
JP2013532830A (ja) 前立腺癌に関するバイオマーカー及びそれを使用する方法
JP2011515666A (ja) トリプルネガティブ乳がんに関連するdna修復タンパク質およびその使用法
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
US20220260585A1 (en) Controlling Intersample Analyte Variability in Complex Biological Matrices
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
Han et al. Development and validation of a decision tree classification model for the essential hypertension based on serum protein biomarkers
WO2014153442A2 (en) Methods and systems for treatment of ovarian cancer
EP3295176A1 (en) Biomarkers for detection of tuberculosis risk
WO2016123058A1 (en) Biomarkers for detection of tuberculosis risk
KR20250039409A (ko) 난소암의 검출 및 치료를 위한 방법
CN111763736B (zh) 用于诊断甲状腺乳头状癌淋巴结转移的液体活检试剂盒
US20250116676A1 (en) Phosphopeptide/phosphoprotein signature predicting basal-like breast cancer recurrence
EP4630819A1 (en) Protein biomarkers for prognosis of liver fibrosis
HK40090190A (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40026777B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902